Effect of dual (alpha/gamma) peroxisome proliferator-activated receptor activator muraglitazar (MURA) therapy in patients with type 2 diabetes mellitus (Abstract/Poster in atti di convegno)

Type

• Prodotto della ricerca (Classe)
• Abstract/Poster in atti di convegno (Classe)

Label

• Effect of dual (alpha/gamma) peroxisome proliferator-activated receptor activator muraglitazar (MURA) therapy in patients with type 2 diabetes mellitus (Abstract/Poster in atti di convegno) (literal)

Anno

• 2007-01-01T00:00:00+01:00 (literal)

Alternative label

• Fernandez M.; Cersosimo E.; Gastaldelli A.; Defronzo R. (2007)
  Effect of dual (alpha/gamma) peroxisome proliferator-activated receptor activator muraglitazar (MURA) therapy in patients with type 2 diabetes mellitus
  in 43rd EASD Annual Meeting, Amsterdam
  (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori

• Fernandez M.; Cersosimo E.; Gastaldelli A.; Defronzo R. (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#note

• In: 43rd EASD Annual Meeting (Amsterdam, 17-21 September 2007). Proceedings, pp. S374 - S374. EASD (ed.). EASD, 2007. (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#descrizioneSinteticaDelProdotto

• Background and Aims: We evaluated the effect of muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor (PPAR) activator within the new glitazar class, on glucose and lipid metabolism. Materials and Methods: A double-blind, randomized controlled trial was performed in 27 patients with type 2 diabetes. Patients received once-daily doses of either 5 mg muraglitazar or placebo plus diet for 16 weeks. Before and after treatment patients underwent: (i) euglycemic hyperinsulinemic clamp combined with tracer infusion to assess endogenous glucose production (EGP) and disposal, and to estimate adipose tissue (Adip-IR=fasting plasma FFA X insulin conc (FPI)) and liver (Hep-IR=EGP x FPI) indices of insulin resistance (IR); (ii) lean and fat body mass quantification by DXA; (iii) liver and visceral fat measurement by MRI/MRS. Results: MURA treatment improved fasting glycemia (-43 mg/dl, p0.001), HbA1c (-1.9%, p (literal)

Titolo

• Effect of dual (alpha/gamma) peroxisome proliferator-activated receptor activator muraglitazar (MURA) therapy in patients with type 2 diabetes mellitus (literal)

Prodotto di

• Tassonomia clinica molecolare - Tassonomia clinica molecolare (ME.P05.003.001) (Modulo)
• Institute of clinical physiology (IFC) (Istituto)

Autore CNR

• AMALIA GASTALDELLI (Persona)

Insieme di parole chiave

• Parole chiave di "Effect of dual (alpha/gamma) peroxisome proliferator-activated receptor activator muraglitazar (MURA) therapy in patients with type 2 diabetes mellitus" (Insieme di parole chiave)

Incoming links:

Autore CNR di

• AMALIA GASTALDELLI (Persona)

Prodotto

• Institute of clinical physiology (IFC) (Istituto)
• Tassonomia clinica molecolare - Tassonomia clinica molecolare (ME.P05.003.001) (Modulo)

Insieme di parole chiave di

• Parole chiave di "Effect of dual (alpha/gamma) peroxisome proliferator-activated receptor activator muraglitazar (MURA) therapy in patients with type 2 diabetes mellitus" (Insieme di parole chiave)